Regulation may contribute to high drug costs, but there are several ways in which regulators at the European Medicines Agency believe they can contribute to keeping drug spending sustainable, beginning with approving genetics and biosimilars more rapidly.
No takes yet. Share an insight, caveat, or question.
Eichler et al. (2016) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: